Drug Discovery

Selected news for the healthcare topic - Drug Discovery, collected since 10/2019. This healthcare topic shares news with Oncology, COVID-19, Biotech, Genomics, Biopharma and hundreds of others.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/23/2022 Lexicon Pharmaceuticals (NASDAQ:LXRX) Raised to Hold at Zacks Investment Research - Transcript Daily transcriptdaily.com ... from a sell rating to a hold rating in a research note released on Thursday morning, Zacks.com reports.According to Zacks, “Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses ...
1/22/2022 Lexicon Pharmaceuticals (NASDAQ:LXRX) Raised to “Hold” at Zacks Investment Research theenterpriseleader.com ... a “sell” rating to a “hold” rating in a research report issued on Thursday, Zacks.com reports.According to Zacks, “Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses ...
1/22/2022 Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Increased to Hold at Zacks Investment Research dispatchtribunal.com Lexicon Pharmaceuticals (NASDAQ:LXRX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Thursday, Zacks.com reports.According to Zacks, “Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library ...
1/21/2022 Drug Discovery Market VALUATION TO BOOM THROUGH 2025 hitechnewsdaily.com The Global Drug Discovery Drug Discovery Market research report offers extensive research and analysis of key aspects of the global Drug Discovery Drug Discovery sample/4689049?utmsource=HTN&utmmedium=rajshree Drug Discovery industry. It mentions their strategic initiatives and offers a brief about their business.Key Players in TheDrug Discovery Covers: Covance, Merck & Co., GenScript, Boehringer Ingelheim, INC, Novartis, Pfizer, Johnson and Johnson, Viva Biotech (Shanghai) Ltd., Evotec ...
1/21/2022 Techpoint Build Spotlight: 54Gene is developing advanced health technologies for Africa techpoint.africa ... what’s to come in health research.Can you tell us more about 54Gene?54gene is a health technology company working to ensure that Africa, a genetically diverse population, is adequately represented in global drug discovery and other clinical research endeavours so as to improve diagnostics and treatment outcomes for Africans and the global community.How would you explain your startup’s value offering to a five-year-old?54gene ...
1/21/2022 Multicomponent double Mannich alkylamination involving C(sp 2 )–H and benzylic C(sp 3 )–H bonds Nature ... structural diversity, molecular complexity and drug-likeness. Therefore, this work opens a distinctive vision for the alkylamination of unactivated C(sp3)−H bonds, and provides a powerful tool in diversity-oriented synthesis (DOS) and drug discovery .IntroductionAlkylamines are fundamental compounds in pharmaceuticals, materials, and agrochemicals 1 , 2 . For their synthesis, the Mannich reaction represents one of the most efficient ...
1/21/2022 The Role Of Bioinformatics In Bringing Biobanks To The Forefront Of Scientific Breakthroughs bio-itworld.com The Role Of Bioinformatics In Bringing Biobanks To The Forefront Of Scientific BreakthroughsContributed Commentary by Zachary Pitluk, Paradigm4January 21, 2022 Life science researchers and drug discovery scientists today work in what, in my view, will be remembered in the future as the beginning of a “golden era” where the power of genetic information is connected to a wide range of other healthcare and lifestyle data to support ...
1/21/2022 Genome Editing Market worth $11.2 billion by 2025 PRSync ... Market worth $11.2 billion by 2025[Marketsandmarkets - HC][Rosy] .According to the new market research report Genome Editing Market by Technology (CRISPR, TALEN, ZFN, Antisense), Product & Service, Application (Cell Line Engineering, Genetic Engineering, Diagnostics, Drug Discovery & Development), End-User and Region - Global Forecast to 2025, published by MarketsandMarkets‚Ñ¢, the global Genome Engineering Market is projected to reach USD 11.2 billion in 2025 from USD 5.1 billion in 2020, at ...
1/21/2022 Drug Discovery Services Market 2022 Comprehensive Growth, Industry Share-Size Estimate, Consumption Analysis by Applications, Future Demand, Top Leading Players, Emerging Trends and Forecast heraldkeeper.com Drug Discovery Services Market 2022 Comprehensive Growth, Industry Share-Size Estimate, Consumption Analysis by Applications, Future Demand, Top Leading Players, Emerging Trends and ForecastReport Ocean presents a new report on Drug Discovery Services market size, share, growth, industry trends, and forecast 2026, covering various industry elements and growth trends helpful for predicting the market’s future.Global Drug Discovery Services Market By Type (Medicinal Chemistry Services, Biology Services, Pharmacokinetics ...
1/21/2022 10x Genomics Adds Global Clinical Research Organizations to Expanded Certified Service Provider Network PR Newswire ... 2 Solutions, Azenta Life Sciences, and CellCarta."10x Genomics' single-cell and spatial technologies are trusted by leading biotechs and the top 20 global pharmaceutical companies to provide actionable insights at every stage of drug discovery and development," said Brad Crutchfield , chief commercial officer of 10x Genomics. "Our biopharmaceutical customers recognize the significant impact and value of single-cell and spatial analysis and have asked for more support incorporating multiomics ...
1/21/2022 10x Genomics Adds Global Clinical Research Organizations to Expanded Certified Service Provider Network | 2022-01-21 | Press Releases stockhouse.com ... 2 Solutions, Azenta Life Sciences, and CellCarta."10x Genomics' single-cell and spatial technologies are trusted by leading biotechs and the top 20 global pharmaceutical companies to provide actionable insights at every stage of drug discovery and development," said Brad Crutchfield , chief commercial officer of 10x Genomics. "Our biopharmaceutical customers recognize the significant impact and value of single-cell and spatial analysis and have asked for more support incorporating multiomics ...
1/21/2022 Compugen (NASDAQ:CGEN) Downgraded by Zacks Investment Research to “Sell” - Watch List News watchlistnews.com ... is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery . “Get Compugen alerts: Separately, JMP Securities reaffirmed a buy rating and set a $18.00 target price on shares of Compugen in a research note on Monday, November 15th.Shares of NASDAQ CGEN opened ...
1/21/2022 RNAi Technology Market Growth, Industry Outlook & Opportunities | DataM Intelligence einnews.com ... rnai-technology-market]Market DynamicsThe worldwide RNAi Technology marketplace growth is driven via numerous factors, together with growing genetic and metabolic issues, growing molecular diagnostics packages, cancer, and developing research & improvement sports for drug discovery .Increasing incidences of most cancers are driving the call for stronger molecular diagnostics. According to the National Cancer Institute estimations, around 1,735,350 new cancer instances were identified in 2018 in the United States, and ...
1/21/2022 Fewer Breakthrough COVID-19 Infections, Lower Risk of Hospitalization in Those Who Received Moderna Vaccine Compared to Pfizer–BioNTech healthnewsdigest.com ... American Medical Association . The study examines breakthrough SARS-CoV-2 infections, hospitalizations and death rates when the Delta variant was predominant.Rong Xu, professor of bioinfomatics and director of the Center for AI in Drug Discovery at the Case Western Reserve School of Medicine and study author, said the study analyzed electronic health records of more than 637,000 fully vaccinated patients from 63 healthcare organizations across the United States, covering ...
1/20/2022 Compugen (NASDAQ:CGEN) Downgraded by Zacks Investment Research to Sell - Mayfield Recorder Mayfield Recorder ... is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery . “Get Compugen alerts: Separately, JMP Securities reissued a buy rating and set a $18.00 price target on shares of Compugen in a research note on Monday, November 15th.CGEN stock opened at $3.81 ...
1/20/2022 Palleon Pharmaceuticals Announces IND Clearance for First-in-Class Cancer Immunotherapy Leveraging Glyco-Immunology | Business | The Daily News galvnews.com ... from a promising, nascent scientific field to an entirely new class of medicines,” said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. “We continue to leverage our unrivaled expertise in glycobiology drug discovery and development to expand our product pipeline in the pursuit of better therapies for patients with cancer and inflammatory diseases.”E-602 is a first-in-class engineered human sialidase enzyme genetic fusion ...
1/20/2022 Illumina Collaborates With Nashville Biosciences to Accelerate Medicines Development csrwire.com ... on the samples and upload the data to the Illumina Connected Analytics platform. Together, Nashville Biosciences and Illumina will establish a commercial alliance of multiple pharmaceutical and biotechnology partners to analyze the data for drug discovery and therapy development. /p blockquote p "Nashville Biosciences' enriched biobank data, coupled with Illumina's extensive genomics and bioinformatics expertise, will enable scientists and researchers to generate new insights into disease and develop new medicines ...
1/20/2022 14th Annual Biotech Showcasetm Brings Together One of The Largest, Most Informative Biotech Investment Conferences Virtually tradingforkeeps.com ... attendees to explore impactful trends, engage insightful personalities, discover innovative companies, and meet motivated investors. Among attendees were nearly 60 members of the press.In an annual event meant to drive the future of drug discovery and development, this year’s participants engaged in 40 program sessions and panels and generated more than 54,000 partnering meeting requests delivered through the partneringONE® meeting platform.Taking place virtually nearly two years ...
1/20/2022 14th Annual Biotech Showcase™ Brings Together One of The Largest, Most Informative Biotech Investment Conferences Virtually | News | bakersfield.com bakersfield.com ... attendees to explore impactful trends, engage insightful personalities, discover innovative companies, and meet motivated investors. Among attendees were nearly 60 members of the press.In an annual event meant to drive the future of drug discovery and development, this year’s participants engaged in 40 program sessions and panels and generated more than 54,000 partnering meeting requests delivered through the partneringONE® meeting platform.Taking place virtually nearly two years ...
1/20/2022 14th Annual Biotech Showcase™ Brings Together One of The Largest, Most Informative Biotech Investment Conferences Virtually | Business | The Daily News galvnews.com ... attendees to explore impactful trends, engage insightful personalities, discover innovative companies, and meet motivated investors. Among attendees were nearly 60 members of the press.In an annual event meant to drive the future of drug discovery and development, this year’s participants engaged in 40 program sessions and panels and generated more than 54,000 partnering meeting requests delivered through the partneringONE® meeting platform.Taking place virtually nearly two years ...